Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Change in Receivables: 2013-2025

Historic Change in Receivables for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to $4.3 million.

  • Coherus Oncology's Change in Receivables rose 154.64% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.2 million, marking a year-over-year decrease of 223.12%. This contributed to the annual value of -$149.3 million for FY2024, which is 199.12% down from last year.
  • Coherus Oncology's Change in Receivables amounted to $4.3 million in Q3 2025, which was up 107.72% from -$55.3 million recorded in Q2 2025.
  • Coherus Oncology's Change in Receivables' 5-year high stood at $75.3 million during Q3 2023, with a 5-year trough of -$76.6 million in Q2 2024.
  • Over the past 3 years, Coherus Oncology's median Change in Receivables value was -$8.5 million (recorded in 2023), while the average stood at -$9.1 million.
  • As far as peak fluctuations go, Coherus Oncology's Change in Receivables surged by 3,084.96% in 2023, and later tumbled by 493.20% in 2025.
  • Over the past 5 years, Coherus Oncology's Change in Receivables (Quarterly) stood at -$13.3 million in 2021, then skyrocketed by 240.91% to $18.8 million in 2022, then skyrocketed by 134.38% to $44.1 million in 2023, then tumbled by 227.85% to -$56.3 million in 2024, then skyrocketed by 154.64% to $4.3 million in 2025.
  • Its Change in Receivables was $4.3 million in Q3 2025, compared to -$55.3 million in Q2 2025 and -$50.9 million in Q1 2025.